scholarly journals Pollen allergy and household budget

2011 ◽  
Vol 8 (4) ◽  
pp. 79-83
Author(s):  
M A Mokronosova ◽  
M A Mokronosova
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Specific Immunotherapy ◽  
Birch Pollen ◽  
Pollen Allergy ◽  
Direct Costs ◽  
Middle Part ◽  
Allergen Specific Immunotherapy ◽  
Severity Of The Disease

The prevalence of the allergy to birch pollen is high in the middle part of russian Federation. the symptoms of allergic intermittent rhinitis appears in the first decade and lasted during all life. the severity of the disease is aggravated annually. the economic burden of allergic rhinitis includes direct, indirect and hidden costs. the indirect cost (disability and loss of productivity, hypoallergenic life arrangements) exceeds direct costs many times. allergen specific immunotherapy by pollen allergovaccines is unique kind of pathogenic management. asIt demonstrates significant improvement of the symptoms of rhinitis and asthma, quality of life. one of the main problems is high costs of asIt. economical models used in investigations on asIt cost effectiveness demonstrated lucre in the following 10 years of life after 3 year's course of asIt. In order to achieve high clinical result it is necessary to follow european standard's guidance on specific immunotherapy strictly.

scholarly journals Efektivitas imunoterapi terhadap gejala, temuan nasoendoskopik dan kualitas hidup pasien rinosinusitis alergi

2012 ◽  
Vol 42 (2) ◽  
Author(s):  
Yuwan Pradana ◽  
Teti Madiadipoera ◽  
Melati Sudiro ◽  
Arif Dermawan
Keyword(s):  
Quality Of Life ◽  
Visual Analogue Scale ◽  
Disease Severity ◽  
Analogue Scale ◽  
Specific Immunotherapy ◽  
Drug Intake ◽  
Allergen Specific Immunotherapy ◽  
Nasal Symptoms ◽  
Severity Of The Disease

Background: Rhinosinusitis is one of major health problems which increased the economic burden. With symptoms include nasal congestion, rhinorrhea, facial pain, and sometimes reduced or loss of smell, this condition may impair work productivity and quality of life (QOL). Rhinosinusitis is one of the comorbidity of allergic rhinitis. Allergen specific immunotherapy provides protection against the occurence of allergic symptoms and inflammatory reactions due to allergen exposure, that results in improvement  of QOL of allergic rhinosinusitis patients.   To assess the effectiveness of immunotherapy in the  severity of the disease, nasal symptoms, nasoendoscopic findings, drugs intake, and the QOL in allergic rhinosinusitis patients treated with specific immunotherapy. Methods: A retrospective descriptive study conducted at the Rhinology-Allergy Clinic of ORL-HNS Department, Dr.Hasan Sadikin General Hospital, Bandung, on January - December 2011, towards 25 patients, by anamnesis, severity of the disease using Visual Analogue Scale (VAS), nasal symptoms from Weeke, Davis and Okuda, nasoendoscopic findings from Lund-Kennedy, drug intake score, and QOL assesment using Rhinoconjuctivitis Quality of Life Questionaire. Results: There was a significant correlation (p<0,05) between specific immunotherapy for 1 year observed by reduced disease severity, reduced nasal symptoms, nasoendoscopic findings improvement, reduced drug intake, and increased Quality of Life which shows significant results from 3 months after immunotherapy using Wilcoxon differential test (p<0,001). Conclusion: Immunotherapy for 1 year was significantly reduced disease severity, reduced nasal symptoms, improved nasoendoscopic findings, reduced drug intake, and improvement of QOL in patients with allergic rhinosinusitis began from 3 months after immunotherapy and maintained afterwards. Key words: allergic rhinosinusitis, nasal symptoms, nasoendoscopy, specific immunotherapy, quality of life    Abstrak :  Latar belakang: Rinosinusitis merupakan salah satu masalah kesehatan yang semakin meningkat sehingga menjadi beban besar terhadap perekonomian masyarakat. Dengan gejala berupa hidung tersumbat, rinore, nyeri pada wajah dan dapat disertai berkurang atau hilangnya penciuman, kondisi ini dapat menurunkan produktivitas kerja dan kualitas hidup. Rinosinusitis merupakan salah satu komorbiditas dari rinitis alergi. Imunoterapi alergen spesifik bertujuan untuk memberikan perlindungan terhadap timbulnya gejala alergi dan reaksi inflamasi akibat pajanan alergen, sehingga dapat meningkatkan kualitas hidup pasien rinosinusitis. Tujuan: Membuktikan efektivitas imunoterapi terhadap tingkat beratnya penyakit, gejala hidung, nasoendoskopi, penggunaan obat dan kualitas hidup pasien rinosinusitis alergi yang diberikan pengobatan imunoterapi selama 3, 6, dan 12 bulan. Metode: Dilakukan penelitian deskriptif retrospektif, di Poliklinik Rinologi Alergi Ilmu Kesehatan THT-KL RSHS Bandung, dalam periode JanuariDesember 2011 pada 25 pasien, menggunakan anamnesis, tingkat berat penyakit berdasarkan Visual Analogue Scale (VAS), gejala hidung  berdasarkan Weeke, Davis dan Okuda, pemeriksaan nasoendoskopi berdasarkan Lund-Kennedy, penggunaan obat dan penilaian kualitas hidup dengan Rhinoconjuctivitis Quality of Life Questionaire. Hasil: Didapatkan hubungan bermakna berdasarkan uji chi-kuadrat-Friedman   antara imunoterapi selama 1 tahun (p<0,05) terhadap penurunan tingkat berat penyakit, penurunan gejala hidung, perbaikan temuan nasoendoskopi, penurunan penggunaan obat, serta peningkatan kualitas hidup. Didapat perbaikan secara bermakna sejak 3 bulan pasca imunoterapi (p<0,001) berdasarkan uji beda Wilcoxon. Kesimpulan: Imunoterapi selama 1 tahun efektif terhadap penurunan tingkat berat penyakit, penurunan gejala hidung, perbaikan temuan nasoendoskopi, penurunan penggunaan obat, serta peningkatan kualitas hidup pada pasien rinosinusitis alergi, dengan perbaikan sejak 3 bulan dan bertahan hingga 1 tahun pasca-imunoterapi. Kata kunci: rinosinusitis alergi, gejala hidung, nasoendoskopi, imunoterapi, kualitas hidup 

scholarly journals Allergen-specific immunotherapy for local allergic rhinitis: a systematic review and meta-analysis

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
M.P. Hoang ◽  
J. Samuthpongtorn ◽  
W. Chitsuthipakorn ◽  
K. Seresirikachorn ◽  
K. Snidvongs
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Symptom Score ◽  
Observational Studies ◽  
Specific Immunotherapy ◽  
Allergen Specific Immunotherapy ◽  
Local Allergic Rhinitis ◽  
Medication Score ◽  
Disease Specific

Background: Local allergic rhinitis (LAR) is a phenotype of chronic rhinitis exhibiting a local Th2-driven inflammation without positive clinical markers of atopy. Immunomodulatory effects of allergen-specific immunotherapy (AIT) induce allergen-specific tolerance. However, AIT is not well-recognized as a treatment for LAR. Methodology: Systematic search on six electronic databases and registries was performed. Experimental and observational studies of AIT for LAR patients were retrieved. The primary outcomes were symptom score, medication score, combined symptom medication score, and disease-specific quality of life. Secondary outcomes were serum specific(s) IgG4, sIgE, and adverse events. Results: Four double-blind randomized controlled trials (156 patients) from two research units assessed the effects of subcutaneous immunotherapy (SCIT). Compared with placebo, SCIT showed significant reductions in symptom score, medication score, combined symptom medication score, disease-specific quality of life, and an increase in serum sIgG4. There was no significant change in serum sIgE. Likewise, two observational studies (one using SCIT and one using sublingual immunotherapy) improved post-therapeutic symptom score. No studies assessed the effects after discontinuation of treatment. AIT was safe without serious adverse events. Conclusion: AIT has beneficial effects and safe for LAR. Its effects are restricted to studies with short-term follow-up. AIT may be considered in LAR patients.

scholarly journals Efficacy of Allergen Specific Immunotherapy for Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis

2021 ◽  
pp. 200-213
Author(s):  
Madonna Nader Adly ◽  
Mahmoud Fawzy Mandour ◽  
Mahmoud Foad Abd Elaziz ◽  
Magdy Eisa Saafan
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Allergic Rhinitis ◽  
Sample Size ◽  
Full Text ◽  
Sublingual Immunotherapy ◽  
Current Evidence ◽  
Eligibility Criteria ◽  
Allergen Specific Immunotherapy

Background: Allergic rhinitis is a common disease that affect nose causing sneezing, watery nose, nasal itching and redness that affect quality of life, productivity at work or school and may underlies complications (e.g. Asthma) for patients and are often accompanied by itchy eye, redness and lacrimation. Aim of the Work: The objective of this study is to systematically assess the efficacy and safety of immunotherapy treatment for patients with Allergic Rhinitis. Method: Our initial search generated a total of 23330 possible relevant titles. Titles, abstracts were preliminary screening so that 22565 were excluded. 154 articles were retrieved in full text the number of studies excluded after assessment of the full text 145, 9 articles met the eligibility criteria and fulfilled the inclusion and exclusion criteria for the review. Data Sources: Medline databases (PubMed, Medscape, ScienceDirect. EMF-Portal) and all materials available on the Internet upto 2018. Data Extraction: If the studies did not fulfill the inclusion criteria, they were excluded. Study quality assessment included whether ethical approval was gained, eligibility criteria specified, appropriate controls, and adequate information and defined assessment measures. Conclusion: Our systematic review provides evidence that Sublingual Immunotherapy (SLIT) tablets effectively relieve rhinitis symptoms in adults with allergic rhinitis, improve their quality of life and provide data about safety of Sublingual Immunotherapy as there were no serious side effects of using SLIT tablets. Nevertheless, the current evidence may be limited due to sample size and the heterogeneity between studies. Large sample size and multiple center RCTs on the efficacy of different formulations of SLIT drugs are still needed to provide further evidence and more precise recommendations.

scholarly journals Determinants and Factors of Satisfaction with Sublingual Immunotherapy in Patients with Allergic Rhinitis

Folia Medica ◽  
2020 ◽  
Vol 62 (2) ◽  
pp. 385-390
Author(s):  
Silviya Novakova
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Visual Analog Scale ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Pollen Allergy ◽  
Analog Scale ◽  
Grass Pollen Allergy ◽  
Satisfaction With Treatment

Introduction: Allergen specific immunotherapy provides effective treatment of allergic rhinitis. Despite its efficacy, it can be signifi&shy;cantly compromised by a possible treatment dissatisfaction of patients. Aim: To explore determinants and factors of satisfaction with sublingual immunotherapy in patients with allergic rhinitis. Materials and methods: A total number of 191 patients with allergic rhinitis who completed a three-year course of sublingual im&shy;munotherapy were included in the study. Of these, 76 had house dust mite (HDM) allergy - 42 men (55.26%) and 115 had grass pollen allergy - 63 men (54.78%) (mean age 27.3 years, SD: 6.14). The patients assessed their satisfaction using a visual analog scale. Health- Related Quality of Life was assessed by Rhinoconjunctivitis Quality of Life questionnaire. A visual analog scale was used to determine severity of the allergic rhinitis. Results: The mean overall satisfaction, compared with that in previous therapy, increased significantly from 4.80 (SD 2.16) to 7.47 (SD 2.05) in the grass pollen allergy group and from 3.42 (SD 2.31) to 7.61 (SD 2.38) in the patients with HDM SLIT (p< 0.001). No relation between satisfaction and sex, type of immunotherapy extracts and duration of the disease was established. A strong correlation was found between satisfaction with treatment and quality of life (R=0.62) and severity of allergic rhinitis (R=0.69) after a three-year course. Conclusion: The results of this real-life study demonstrated that most patients with allergic rhinitis appeared to be satisfied with a three-year course of sublingual immunotherapy. The study provided evidence that reduction in severity of symptoms and improvement in quality of life could determine satisfaction with treatment.

Sign in / Sign up

Export Citation Format

Share Document